Clinical Trial Update: Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating intravesical HDAC inhibition to enhance response to immuno-oncology agents in bladder cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• HDAC inhibitor (intravesical)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Bladder Cancer | Phase 1 | Status: SUSPENDED